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To the Editor: Crimean-Congo 
hemorrhagic fever (CCHF) is an acute 
viral infection that causes mild to se-
vere hemorrhagic fever characterized 
by petechiae, ecchymosis, dissemi-
nated intravascular coagulation, and 
multi-organ failure (1). The etiologic 
agent, CCHF virus (CCHFV; fam-
ily Bunyaviridae, genus Nairovirus), 
is maintained in enzootic cycles in-
volving agricultural and wild animals 
and the vector, Hyalomma ticks. (2). 
CCHF predominantly affects persons 
who have 1) substantial contact with 
ticks and/or agricultural animals in 
areas where CCHF is endemic or 2) 
close contact with infected persons, 
predominantly close relatives and 
health care workers. The case-fatality 
rate for CCHF is generally accepted as 
30% (1).
CCHF has a wide geographic 
distribution; cases have been reported 
in >30 countries across Africa, south-
eastern Europe, the Middle East, and 
western Asia. In the western African 
countries of Nigeria, Mauritania, and 
Senegal, serologic evidence of CCH-
FV infections in humans and agricul-
tural animals has been documented 
frequently (3–5); however, reports of 
the disease in humans have been limit-
ed to Senegal and Mauritania (6,7). In 
neighboring Mali, where the tick vec-
tor is known to be present, little infor-
mation exists regarding the presence 
of CCHFV. Thus, to determine if the 
virus is circulating undetected in Mali, 
we conducted a study to determine if 
CCHFV is present in Hyalomma ticks 
in the country.
In November 2011 and March 
2012, unfed Hyalomma ticks (adults 
and nymphs) were collected from 20 
cattle at the Daral livestock market 
(12° 49.855′ N, 08° 05.651′ W) near 
the town of Kati, Mali, ≈25 km from 
the capital, Bamako. In the field, ticks 
were visually identified to genus and 
pooled accordingly (3–4 ticks per 
pool, all collected from the same ani-
mal). A total of 23 tick pools, repre-
senting 80 ticks, were manually ho-
mogenized, and RNA was extracted 
and tested for the presence of CCHFV 
RNA by using in-house assays that 
selected for 3 virus genes. Of the 23 
tick pools tested, 1 was positive for 
CCHFV by all 3 assays. Phylogenetic 
analysis of the complete nucleocap-
sid protein gene (KF793333) showed 
that the CCHFV strain from Mali 
most closely resembled a strain from 
Mauritania (GenBank accession no. 
ArD39554), sharing 98% sequence 
identity (Figure, panel A). 
Further analysis of fragments of 
the medium segment (pre-Gn cod-
ing region, KF793334) and large 
segment (polymerase coding region, 
KF793335) confirmed these findings, 
showing sequence identities of 91% 
and 98%, respectively, with ArD39554 
(Figure, panels B, C). In a Biosafety 
Level 4 facility at Rocky Mountain 
Laboratories, Hamilton, Montana, 
USA, the original homogenates from 
the positive pool were passaged in 
multiple cell lines. After 3 passages, no 
discernible cytopathic effect was ob-
served and, aside from the initial pas-
sage, CCHFV RNA was not detected.
Genetic identification of ticks in 
the CCHFV RNA–positive pool was 
conducted as described (8,9). Ampli-
fied sequences most closely resem-
bled those of H. dromedarii, (97.2%–
100% sequence identity), although 
genetically, we cannot exclude the 
possibility that H. truncatum and H. 
rufipes were present with individual 
sequence identities of >97% to pub-
lished sequences.
The Daral cattle market in Kati 
is the largest of its kind in Mali, and 
animals from across the country come 
into the market every week. Although 
the market provided a convenient 
opportunity for collecting ticks, we 
cannot determine where the infected 
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ticks, and possibly cattle, contracted 
CCHFV because the animals tra-
versed great distances on foot before 
arriving at the market. Nevertheless, 
this study demonstrates the presence 
of a distinct strain of CCHFV in Hya-
lomma ticks in Mali, thereby expand-
ing the geographic distribution of this 
virus in western Africa. Not surpris-
ingly, the highest sequence identity 
for the CCHFV strain from Mali is to 
strains known to circulate in neighbor-
ing countries (10). We propose Daral 
2012 Mali as the temporary designa-
tion for this sequence. Unfortunately, 
our attempts to isolate the virus were 
unsuccessful, most likely because of 
processing and storage conditions for 
homogenates used in these studies.
Species of Hyalomma ticks are 
widely distributed across western Af-
rica, and although reports of CCHF 
are limited to a few countries, CCHFV 
is most likely circulating undetected 
in vast areas of this region. No cases 
of CCHF have been reported in Mali; 
however, on the basis of our findings, 
the potential for human infections ex-
ists. Thus, CCHF should be considered 
in the differential diagnosis of febrile 
illnesses, with or without hemorrhagic 
symptoms, in residents of Mali and for 
persons with a recent history of travel 
to this country.
The ease of CCHFV transmis-
sion and the high case-fatality rate 
associated with infection could have 
a potentially substantial effect on pub-
lic health. Future studies in Mali are 
required to define the geographic dis-
tribution of infected ticks and animals 
and to isolate CCHFV to help focus 
public health preparedness and coun-
termeasures. In addition, across Mali, 
operational protocols should be re-
viewed for persons working at jobs in 
which the risk for CCHFV transmis-
sion is high (e.g., occupations with di-
rect contact with agricultural animals 
and/or animal blood products), and 
appropriate countermeasures should 
be put in place to prevent transmission 
among such persons.
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To the Editor: Enterovirus infec-
tions are associated with many clini-
cal manifestations, and specific virus 
groups or serotypes are associated 
with specific manifestations. Cox-
sackievirus A16, a common cause of 
hand, foot and mouth disease, rarely 
causes encephalitis. Although most 
enterovirus infections are cleared by 
cellular immune responses, invasive 
enterovirus disease is prevented or 
controlled by neutralizing antibodies 
(1). Thus, patients with humoral im-
munodeficiencies are susceptible to 
serious enterovirus infections.
Nine cases of enteroviral en-
cephalitis (1 caused by echovirus 13, 
1 caused by coxsackievirus A16, 2 
caused by enterovirus 71, and 5 caused 
by unknown enteroviruses) have been 
reported after therapy with rituximab, 
a monoclonal antibody (MAb) that 
causes secondary hypogammaglobu-
linemia (2). We describe coxsackievi-
rus A16 encephalitis in a patient who 
was receiving treatment with the MAb 
obinutuzumab.
A 67-year-old woman with non-
Hodgkin lymphoma showed complete 
remission after 6 cycles of treatment 
with bendamustine and obinutuzum-
ab. Induction immunochemotherapy 
was followed by obinutuzumab main-
tenance therapy. At admission, she had 
received 7 of 12 scheduled treatments.
The patient was hospitalized be-
cause of a history of high-grade fever 
that did not respond to antimicrobial 
drugs, confusion, general weakness, 
and urinary incontinence. She had a 
neutrophil count of 3.1 × 109 cells/L 
but had severe lymphocytopenia (0.3 
× 109 cells/L and an absolute CD4 cell 
count of 0.082 × 109 cells/L) and low 
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	20,	No.	5,	May	2014	 913
Letters
Letters commenting on recent 
articles as well as letters report-
ing cases, outbreaks, or original 
research are welcome. Letters 
commenting on articles should 
contain no more than 300 words 
and 5 references; they are more 
likely to be published if submitted 
within 4 weeks of the original ar-
ticle’s publication. Letters report-
ing cases, outbreaks, or original 
research should contain no more 
than 800 words and 10 references. 
They may have 1 Figure or Table 
and should not be divided into sec-
tions. All letters should contain 
material not previously published 
and include a word count.
